X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs DISHMAN PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA DISHMAN PHARMA ABBOTT INDIA/
DISHMAN PHARMA
 
P/E (TTM) x 41.1 25.1 163.8% View Chart
P/BV x 10.6 3.3 315.8% View Chart
Dividend Yield % 0.7 0.7 98.3%  

Financials

 ABBOTT INDIA   DISHMAN PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
DISHMAN PHARMA
Mar-16
ABBOTT INDIA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs6,110374 1,631.9%   
Low Rs3,996129 3,100.1%   
Sales per share (Unadj.) Rs1,552.2197.8 784.7%  
Earnings per share (Unadj.) Rs188.821.2 890.3%  
Cash flow per share (Unadj.) Rs196.434.7 565.7%  
Dividends per share (Unadj.) Rs55.002.00 2,750.0%  
Dividend yield (eoy) %1.10.8 137.0%  
Book value per share (Unadj.) Rs796.6179.9 442.8%  
Shares outstanding (eoy) m21.2580.69 26.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.31.3 255.9%   
Avg P/E ratio x26.811.9 225.5%  
P/CF ratio (eoy) x25.77.2 354.9%  
Price / Book Value ratio x6.31.4 453.4%  
Dividend payout %29.19.4 308.9%   
Avg Mkt Cap Rs m107,37620,306 528.8%   
No. of employees `0003.30.8 400.7%   
Total wages/salary Rs m3,9375,355 73.5%   
Avg. sales/employee Rs Th9,929.319,252.7 51.6%   
Avg. wages/employee Rs Th1,185.16,459.5 18.3%   
Avg. net profit/employee Rs Th1,207.72,064.1 58.5%   
INCOME DATA
Net Sales Rs m32,98515,961 206.7%  
Other income Rs m1,170265 440.8%   
Total revenues Rs m34,15516,226 210.5%   
Gross profit Rs m5,2454,103 127.8%  
Depreciation Rs m1621,091 14.8%   
Interest Rs m38944 4.0%   
Profit before tax Rs m6,2152,334 266.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203624 353.2%   
Profit after tax Rs m4,0121,711 234.5%  
Gross profit margin %15.925.7 61.9%  
Effective tax rate %35.426.7 132.6%   
Net profit margin %12.210.7 113.5%  
BALANCE SHEET DATA
Current assets Rs m22,65511,018 205.6%   
Current liabilities Rs m6,6819,517 70.2%   
Net working cap to sales %48.49.4 515.0%  
Current ratio x3.41.2 292.9%  
Inventory Days Days65110 58.6%  
Debtors Days Days2935 83.7%  
Net fixed assets Rs m83516,304 5.1%   
Share capital Rs m213161 131.7%   
"Free" reserves Rs m16,71512,907 129.5%   
Net worth Rs m16,92814,516 116.6%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m24,16229,805 81.1%  
Interest coverage x163.73.5 4,716.0%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.40.5 254.9%   
Return on assets %16.88.9 188.1%  
Return on equity %23.711.8 201.1%  
Return on capital %36.917.5 210.7%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m3694,952 7.4%   
Fx outflow Rs m3,807697 546.3%   
Net fx Rs m-3,4384,255 -80.8%   
CASH FLOW
From Operations Rs m1,5272,786 54.8%  
From Investments Rs m-2,148-1,529 140.5%  
From Financial Activity Rs m-1,024-941 108.8%  
Net Cashflow Rs m-1,646316 -520.1%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 3.7 213.5%  
FIIs % 0.1 12.7 0.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 22.1 77.4%  
Shareholders   18,270 46,261 39.5%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare ABBOTT INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY18); Net Profit Up 137.9% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 137.9% YoY). Sales on the other hand came in at Rs 8 bn (up 10.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Sep 19, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS